Detalhe da pesquisa
1.
Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets.
Mol Cell
; 78(3): 477-492.e8, 2020 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386542
Mostrar mais
Texto completo
2.
Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocations.
Am J Hematol
; 99(6): 1172-1174, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38436141
3.
Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management.
Eur J Haematol
; 111(2): 201-210, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37186398
4.
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Br J Haematol
; 197(1): 52-62, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34997766
5.
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
Eur J Haematol
; 109(1): 90-99, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35403752
6.
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
Br J Haematol
; 193(2): 346-355, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368155
7.
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
Br J Haematol
; 192(1): 62-74, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32449159
8.
Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.
Br J Haematol
; 185(1): 89-92, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30637732
9.
MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia.
Haematologica
; 104(11): 2206-2214, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923102
10.
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Haematologica
; 104(12): 2400-2409, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31073075
11.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
Ann Hematol
; 98(2): 321-330, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30446802
12.
Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.
Br J Haematol
; 182(6): 777-788, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30125955
13.
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
Br J Haematol
; 196(6): e55-e57, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34993961
14.
Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
Br J Haematol
; 197(1): e1-e4, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34923623
15.
How I treat leukemia during pregnancy.
Blood
; 123(7): 974-84, 2014 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24269956
16.
Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Biol Blood Marrow Transplant
; 21(7): 1230-6, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25797175
17.
Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.
Br J Haematol
; 190(1): e9-e11, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32369612
18.
Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
Br J Haematol
; 190(4): e198-e200, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32593183
19.
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.
Br J Haematol
; 191(2): 171-193, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32734668
20.
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Br J Haematol
; 170(1): 29-39, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25824940